Status epilepticus is a seizure that does not stop on its own, or a series of seizures occurring so close together that the person never recovers between them. The formal definition describes it as a failure of the brain’s built-in mechanisms for shutting seizures down, creating a self-sustaining loop that can damage or kill neurons the longer it runs. Once considered simply “a seizure lasting more than 30 minutes,” the clinical threshold for emergency treatment has been pushed much earlier, to roughly five minutes for convulsive seizures, because waiting longer sharply increases the risk of brain injury and makes the episode harder to control with medication.
What Happens in the Brain During a Prolonged Seizure
A normal seizure ends because inhibitory signals in the brain ramp up to counterbalance the runaway electrical firing. The main brake is a neurotransmitter called GABA, which quiets neurons by binding to receptors on their surface. During status epilepticus, something goes wrong with that brake. Research using electrophysiology and cellular imaging has shown that prolonged seizure activity causes GABA receptors to be pulled from the cell surface and tucked away inside the neuron at an accelerated rate. The more intensely the neurons fire, the faster the receptors disappear. The result is a vicious cycle: seizure activity strips away the brain’s main inhibitory mechanism, which allows the seizure to continue, which strips away still more receptors.
1PubMed Central. Status epilepticus increases the intracellular accumulation of GABAA receptorsAt the same time, excitatory pathways gain strength. Excessive calcium floods into neurons through specific receptor channels, activating enzymes that can trigger programmed cell death. This mechanism, called excitotoxicity, is the same process that kills brain cells during a stroke or severe head trauma. It causes irreversible structural damage to neurons and is a major reason why duration matters so much in status epilepticus.
2PubMed Central. Programmed mechanisms of status epilepticus-induced neuronal necrosisThis dual shift, where inhibition collapses and excitation escalates, also explains why benzodiazepines (which work by boosting GABA receptor activity) become less effective the longer a seizure runs. Treating early, before the receptors are pulled inside the cell, gives those drugs their best shot at working.
What Triggers Status Epilepticus
Status epilepticus is not a disease in itself but a complication of many different conditions. In adults, the most common triggers are acute brain injuries such as stroke and oxygen deprivation after cardiac arrest. People with known epilepsy can develop it when they miss doses of their seizure medication, switch drugs, or encounter an illness that lowers their seizure threshold. Infections, brain tumors, metabolic disturbances like dangerously low blood sugar or sodium, drug and alcohol withdrawal, and traumatic brain injury round out the list of frequent causes.
3PubMed Central. Acute symptomatic seizures and status epilepticus in older adults: A narrative review focusing on management and outcomesIn children, the picture looks somewhat different. Febrile status epilepticus, a prolonged seizure triggered by fever, is one of the most common forms in young kids. Although most febrile seizures are brief and harmless, a small fraction cross into status epilepticus territory. Research from the large FEBSTAT study has been tracking long-term consequences of these prolonged febrile episodes. While the majority of children who experience febrile seizures do well, recent findings suggest that some serious long-term outcomes, including cognitive and psychiatric effects, may reflect an underlying brain vulnerability that the febrile seizure reveals rather than causes.
4PubMed. Current understanding of febrile seizures and their long-term outcomesA smaller but increasingly recognized group involves autoimmune and inflammatory causes. In new-onset refractory status epilepticus (NORSE), seizures erupt in a previously healthy person with no prior epilepsy, often after a mild febrile illness. Evidence points to immune dysregulation as a driver, and targeted immunotherapy, using drugs like anakinra and tocilizumab that block specific inflammatory molecules, has shown promise. In collected case reports and series covering 75 patients, these treatments achieved seizure control within two weeks in up to about 70% of cases.
5PubMed. Second-line immunotherapy in new onset refractory status epilepticusThe Damage Beyond the Brain
Prolonged convulsive status epilepticus is not just a brain event. The whole body takes a hit. A systematic review of acute complications found that sustained, violent muscle contractions drive up body temperature and blood potassium levels, interfere with coordinated breathing, and can cause oxygen deprivation and a dangerous buildup of acid in the blood. A massive release of stress hormones (catecholamines) can damage heart muscle, sometimes triggering a form of stress cardiomyopathy, and can break down skeletal muscle fibers, releasing proteins that clog the kidneys.
6PubMed. Acute Systemic Complications of Convulsive Status Epilepticus-A Systematic ReviewThese cascading complications span cardiac arrhythmias, respiratory failure, kidney dysfunction, and gastrointestinal problems, and they are often worsened both by the metabolic demands of the seizure itself and by the heavy sedation needed to stop it.
7PubMed. Systemic Complications of Status EpilepticusFirst-Line Treatment and the Underdosing Problem
Benzodiazepines are the universal first-line treatment. The goal is to get the drug into the patient’s bloodstream as quickly as possible, because every minute of ongoing seizure activity erodes the chance of a simple response. A landmark trial involving nearly 900 patients found that an intramuscular injection of midazolam given by paramedics was not only as good as intravenous lorazepam but actually stopped seizures before hospital arrival in a higher proportion of patients: about 73% versus 63%. The practical advantage is that an intramuscular shot can be given immediately, without the delay of starting an IV line in a seizing patient.
8PubMed Central. Intramuscular versus intravenous therapy for prehospital status epilepticusDespite clear evidence that early, adequate dosing of benzodiazepines is the single most important step, real-world practice consistently falls short. A study of emergency department patients found that only 17% received an adequate first dose of a benzodiazepine. Lorazepam was underdosed about 77% of the time, midazolam 90%, and diazepam nearly 97%. The consequences of this timidity were measurable: inadequate total dosing was significantly associated with higher in-hospital mortality.
9PubMed Central. Assessment of benzodiazepine dosing in status epilepticus patients in the emergency departmentThe fear behind underdosing is that benzodiazepines will suppress breathing. But the data suggest this fear is overblown, at least relative to the risk of undertreating. A prehospital study found that higher midazolam doses were actually associated with lower odds of needing rescue therapy and were not linked to increased respiratory complications. If anything, higher doses were associated with a decreased need for breathing support after adjustment.
10PubMed Central. Prehospital midazolam use and outcomes among patients with out-of-hospital status epilepticusThe paradox is intuitive once you think about it: a seizing patient who keeps seizing is at far greater respiratory risk than a patient whose seizure has been aggressively terminated. Underdosing benzodiazepines does not protect the airway; it prolongs the threat to it.
When the First Drug Fails
Roughly a third to half of patients will still be seizing after adequate benzodiazepine treatment. For these cases, a second-line anticonvulsant is added. The three main contenders are levetiracetam, fosphenytoin (or its older form phenytoin), and valproate. A major randomized trial, the ESETT study, compared all three head-to-head in patients whose seizures had not responded to benzodiazepines. The results were strikingly similar: seizure cessation with improved consciousness at 60 minutes was achieved in about 47% with levetiracetam, 45% with fosphenytoin, and 46% with valproate. No drug emerged as clearly superior.
11PubMed Central. Randomized Trial of Three Anticonvulsant Medications for Status EpilepticusAn age-stratified analysis of the same trial confirmed this parity across children, adults, and older adults. If anything, response rates were modestly lower in older adults regardless of which drug they received, likely because older patients more often have serious underlying brain injuries driving their seizures.
12The Lancet. Comparative efficacy and safety of levetiracetam, fosphenytoin, and valproate for established status epilepticus in children and adultsA network meta-analysis that pooled 23 randomized trials added a wrinkle: phenobarbital ranked highest for seizure control among the second-line agents, substantially outperforming the other four drugs analyzed. Phenobarbital carries more sedation and respiratory depression risk, which has historically kept it from being the default choice in many settings, but these findings have renewed interest in using it more liberally, particularly where close monitoring is available.
13PubMed Central. Comparative efficacy and safety of second-line medications for status epilepticus: A network meta-analysisRefractory and Super-Refractory Status Epilepticus
When both first-line and second-line drugs fail, the condition is labeled refractory. At this point, the patient typically requires ICU admission and continuous intravenous anesthetics to suppress seizure activity. The usual agents are midazolam drip, propofol, and pentobarbital. A systematic review found that pentobarbital had the lowest short-term treatment failure rate (about 8% versus 23% for midazolam or propofol) and fewer breakthrough seizures, but it caused dangerously low blood pressure far more often.
14PubMed. Treatment of refractory status epilepticus with pentobarbital, propofol, or midazolam: a systematic reviewFor continuous midazolam infusion specifically, higher doses appear to pay off. A study comparing dosing strategies found that patients treated with higher-dose midazolam had dramatically fewer seizures recurring within 48 hours of stopping the drip (15% versus 64%) and lower discharge mortality (40% versus 62% after adjusting for other factors). The trade-off was more frequent episodes of low blood pressure, but these did not translate into worse overall outcomes.
15PubMed Central. High-dose midazolam infusion for refractory status epilepticusWhen seizures persist for 24 hours or more despite anesthetic treatment, the label shifts again to super-refractory status epilepticus. This is a particularly grim situation, with high mortality and limited proven therapies. Ketamine, which works through a completely different receptor system than benzodiazepines or traditional anesthetics, has emerged as one of the more promising options. In a study of 68 patients with super-refractory status epilepticus, ketamine reduced seizure burden by at least half within 24 hours in about 81% of patients, and seizures stopped entirely in 63%.
16PubMed Central. Ketamine to treat super-refractory status epilepticusBeyond ketamine, a wide range of last-resort interventions have been tried for super-refractory cases, including therapeutic hypothermia (cooling the body), the ketogenic diet, emergency brain surgery, electrical stimulation, steroids and other immunosuppressive drugs, and magnesium infusion. Evidence for most of these remains thin, drawn largely from case reports and small series rather than controlled trials.
17PubMed Central. Super-Refractory Status Epilepticus: Prognosis and Recent Advances in ManagementThe Non-Convulsive Form That Gets Missed
Not all status epilepticus looks like the dramatic, full-body shaking most people picture. Non-convulsive status epilepticus produces continuous or near-continuous electrical seizure activity in the brain without obvious external convulsions. The patient may appear confused, drowsy, or simply “off,” and in an ICU setting it can easily be mistaken for the effects of sedation or the underlying illness. Detecting it requires continuous brain-wave monitoring (EEG), because the seizures are invisible at the bedside. Delays in diagnosis are associated with worse outcomes, making EEG monitoring an essential tool for at-risk ICU patients, including those with head injuries, strokes, brain hemorrhages, and newborns recovering from oxygen deprivation at birth.
18PubMed. Ellen R. Grass Lecture: Rapid EEG analysis for intensive care decisions in status epilepticusEven when anesthetics successfully suppress convulsions, epileptic patterns can persist within the EEG. Research on burst-suppression, the brain-wave pattern clinicians aim for when using heavy sedation, has shown that seizure activity often continues within the “bursts” of electrical activity between the quiet periods. Achieving burst-suppression on the monitor is not itself the treatment goal; the actual goal is stopping all seizure patterns. Spectral analysis of the burst activity can help clinicians tell the difference and personalize how deeply to sedate a given patient.
19PubMed Central. Real-Time Segmentation of Burst Suppression Patterns in Critical Care EEG MonitoringLong-Term Outcomes
Surviving status epilepticus does not mean returning to normal. A critical assessment of long-term outcome studies found that the overall risk of a poor outcome after status epilepticus is high in both children and adults. The single biggest predictor of how someone does afterward is not the seizure duration or the patient’s age but the underlying cause. A person whose status epilepticus was triggered by a massive stroke or cardiac arrest faces far grimmer prospects than someone whose episode resulted from missing epilepsy medication.
20PubMed Central. Long-term outcomes of status epilepticus: A critical assessmentFor people who survive new-onset refractory status epilepticus (NORSE), the long-term burden extends well beyond whether they develop epilepsy afterward. Researchers have mapped outcomes across eight domains: neuropsychological function, other neurological deficits, psychiatric and mood disturbances, quality of life, ongoing seizures, non-neurological medical problems, social functioning, and the burden placed on caregivers. Many survivors face lasting cognitive impairment, personality changes, or chronic epilepsy requiring lifelong medication.
21PubMed Central. New onset refractory status epilepticus: Long-term outcomes beyond seizuresDisparities in Who Gets Status Epilepticus and How It Is Treated
Status epilepticus does not affect all populations equally, and neither does access to optimal care. A national study of hospital admissions found that prevalence per 10,000 admissions was roughly twice as high for non-Hispanic Black patients (about 27) as for non-Hispanic white patients (about 14). People in the lowest income bracket were also more likely to be admitted with the condition. Minority populations had higher odds of requiring a tracheostomy or feeding tube, markers of more severe or more prolonged illness.
22PubMed. Health care disparities in morbidity and mortality in adults with acute and remote status epilepticus: A national studyAccess to EEG monitoring, which is critical for detecting non-convulsive seizures and guiding treatment, showed a stark gradient. The odds of receiving EEG monitoring rose progressively with income and were dramatically higher in urban teaching hospitals than in rural hospitals. Being treated in an urban teaching hospital was associated with roughly 13 times the odds of getting EEG monitoring compared to a rural facility. These gaps suggest that where you live and what resources your hospital has may shape your outcome nearly as much as the seizure itself.
23PubMed. Health care disparities in morbidity and mortality in adults with acute and remote status epilepticus: A national studyHow Neuroimaging Adds to the Picture
Brain imaging, particularly MRI, has become an increasingly important tool in the workup of status epilepticus. It serves a dual purpose: identifying what caused the seizure in the first place (a tumor, a stroke, an area of scarring) and revealing damage caused by the prolonged seizure itself. MRI can show a broad spectrum of abnormalities tied to sustained epileptic activity, some of which are reversible if the seizure is controlled quickly and some of which represent permanent injury. Hemodynamic patterns visible on certain MRI sequences can even support the diagnosis when clinical and EEG findings are ambiguous. Over the past two decades, the use of neuroimaging in status epilepticus has expanded considerably, giving clinicians a window into both the cause and the consequences of the episode in real time.
How Treatment Has Evolved
The history of treating status epilepticus tracks the broader history of neurology and anesthesia. Before the 20th century, the main tools were bromide salts and crude general anesthetics. Barbiturates arrived in the early 1900s, phenytoin in the 1930s, and benzodiazepines in the 1960s. For much of this history, the guiding philosophy was simply to sedate the patient heavily enough to stop visible convulsions, a strategy that advanced alongside improvements in safe anesthesia delivery in the postwar period.
24PubMed. The historical evolution of, and the paradigms shifts in, the therapy of convulsive status epilepticus over the past 150 yearsSince the 1970s, changes in treatment approach have arguably mattered more than any single new drug. The recognition that time is the enemy, that benzodiazepines need to be given early and in adequate doses, that non-convulsive seizures can persist after visible shaking stops, and that EEG monitoring is necessary to confirm true seizure termination, has collectively done more to improve outcomes than any individual medication advance. The current definition of status epilepticus, which frames it as a dynamic failure of seizure-termination mechanisms with time-dependent consequences, reflects this evolution in thinking.
25PubMed. 25 years of advances in the definition, classification and treatment of status epilepticusThe gap between what the evidence recommends and what actually happens at the bedside remains the field’s central frustration. The drugs are reasonably effective when used correctly. The bigger challenge is getting them given fast enough, in high enough doses, to the right patients, regardless of which hospital or neighborhood that patient happens to be in.